[Fibrinolytic herapy of severe pulmonary hypertension. Justification, modality an criticism].
D000707:Anaphylaxis / Q000517:prevention & control; D000906:Antibodies / Q000032:analysis; D001794:Blood Pressure / Q000187:drug effects; D006328:Cardiac Catheterization; D002302:Cardiac Output / Q000187:drug effects; D003864:Depression, Chemical; D001728:Dicumarol / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D011651:Pulmonary Artery; D011877:Radionuclide Imaging; D013268:Stimulation, Chemical; D013300:Streptokinase / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000150:complications; D014655:Vascular Resistance / Q000187:drug effects
D000906:Antibodies; D001728:Dicumarol; D006493:Heparin; D013300:Streptokinase; D011241:Prednisone
Traitement fibrinolytique de l'hypertension pulmonaire sévère. Justification, modalités et critique.